1 Ito M, "The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT" 25 : 1163-1172, 2014
2 Emiko Ifuku, "Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk" 대한골다공증학회 5 (5): 44-50, 2019
3 McClung MR, "Romosozumab in postmenopausal women with low bone mineral density" 370 : 412-420, 2014
4 Nakamura T, "Randomized Teriparatide [human parathyroid hormone(PTH)1-34] Once-Weekly Efficacy Research(TOWER)trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk" 97 : 3097-3106, 2012
5 Tsujimotoa M, "PINP as an aid for monitoring patients treated with teriparatide" 48 : 798-803, 2011
6 Canalis E, "Mechanisms of anabolic therapies for osteoporosis" 357 : 905-916, 2007
7 Zebaze R, "Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide" 99 : 80-84, 2017
8 Fumitoshi Omura, "Impact of patient background factors on the treatment efficacy of once-weekly teriparatide" 대한골다공증학회 5 (5): 51-56, 2019
9 Yamamoto T, "Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice" 157 : 2604-2620, 2016
10 Shiraki M, "Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women" 24 : 219-226, 2013
1 Ito M, "The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT" 25 : 1163-1172, 2014
2 Emiko Ifuku, "Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk" 대한골다공증학회 5 (5): 44-50, 2019
3 McClung MR, "Romosozumab in postmenopausal women with low bone mineral density" 370 : 412-420, 2014
4 Nakamura T, "Randomized Teriparatide [human parathyroid hormone(PTH)1-34] Once-Weekly Efficacy Research(TOWER)trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk" 97 : 3097-3106, 2012
5 Tsujimotoa M, "PINP as an aid for monitoring patients treated with teriparatide" 48 : 798-803, 2011
6 Canalis E, "Mechanisms of anabolic therapies for osteoporosis" 357 : 905-916, 2007
7 Zebaze R, "Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide" 99 : 80-84, 2017
8 Fumitoshi Omura, "Impact of patient background factors on the treatment efficacy of once-weekly teriparatide" 대한골다공증학회 5 (5): 51-56, 2019
9 Yamamoto T, "Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice" 157 : 2604-2620, 2016
10 Shiraki M, "Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women" 24 : 219-226, 2013
11 Neer RM, "Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis" 344 : 1434-1441, 2001
12 Tsai JN, "Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT study" 30 : 39-45, 2015
국립중앙도서관 "우편 복사 서비스"로 연결 됩니다.
KCI
